Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.
It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC.
The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
It also develops SCY-247 to treat systemic fungal diseases.
The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp.
SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.
The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.30 Decreased by -112.20% | -0.20 Decreased by -50.00% |
| May 8, 24 | 0.01 Increased by +101.41% | -0.20 Increased by +105.00% |
| Feb 7, 24 | -0.39 Decreased by -5.41% | -0.20 Decreased by -95.00% |
| Nov 13, 23 | -0.04 Increased by +93.55% | -0.15 Increased by +73.33% |
| Aug 14, 23 | 2.46 Increased by +893.55% | 1.55 Increased by +58.71% |
| May 10, 23 | -0.71 Decreased by -317.65% | -0.28 Decreased by -153.57% |
| Mar 31, 23 | -0.37 Increased by +64.76% | -0.44 Increased by +15.91% |
| Nov 9, 22 | -0.62 Decreased by -3.00 K% | -0.50 Decreased by -24.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 660.00 K Decreased by -62.52% | -2.81 M Decreased by -59.82% | Decreased by -425.45% Decreased by -326.42% |
| Jun 30, 24 | 736.00 K Decreased by -99.44% | -14.46 M Decreased by -111.83% | Decreased by -1.96 K% Decreased by -2.21 K% |
| Mar 31, 24 | 1.37 M Increased by +21.50% | 411.00 K Increased by +100.74% | Increased by +29.93% Increased by +100.61% |
| Dec 31, 23 | 5.80 M Increased by +280.38% | -19.59 M Decreased by -2.39% | Decreased by -337.86% Increased by +73.08% |
| Sep 30, 23 | 1.76 M Increased by +13.10% | -1.76 M Increased by +95.27% | Decreased by -99.77% Increased by +95.82% |
| Jun 30, 23 | 131.45 M Increased by +9.84 K% | 122.26 M Increased by +1.02 K% | Increased by +93.01% Increased by +109.22% |
| Mar 31, 23 | 1.13 M Increased by +64.48% | -55.62 M Decreased by -920.42% | Decreased by -4.92 K% Decreased by -520.38% |
| Dec 31, 22 | 1.52 M Increased by +155.28% | -19.13 M Increased by +34.59% | Decreased by -1.26 K% Increased by +74.38% |